YB new stock pitches (Fri, May 29)

STMicroelectronics (STM), a vertically integrated European IDM with sovereign Western manufacturing across 12 sites, is positioned as the physical infrastructure layer of the AI era through moats spanning six layers of AI data centers: SiC power chips for 800V DC conversion (addressing grid-to-rack efficiency), PIC100 silicon photonics delivering 1.6Tbps optical interconnects on 300mm wafers with 2.3x yield advantage (solving copper's physical limits beyond 1 meter at 224Gbps), and STM32N6 microcontrollers with 600 GOPS Neural-ART accelerators enabling edge AI in collaboration with Nvidia for Physical AI robotics. The company dominates LEO satellite semiconductors with ~90% market share (Starlink supplier), generating $600M in 2025 and tracking toward $1B+ annually with over $3B cumulative space revenue guided through 2028. Q1 2026 delivered $3.1B revenue (+23% YoY) with gross margin recovering to 33.8% and Q2 guided to $3.45B with 35.2% margin as Power & Discrete (P&D) segment recovers from -21.5% operating margin (driven by $416M unused capacity charges in 2025) toward normalized +12% as data center revenue scales from $500M in 2026 to $1B+ in 2027 (40% power/analog, 60% microcontroller/photonics mix). The company closed NXP's $950M MEMS acquisition, partners with Huahong for STM32 wafer production in China, maintains €2B net cash with €4.57B liquidity, and targets ~$17.7B revenue with 20% EBIT margin and P&D reaching +12% margins as underutilization costs drop to $25M by 2027, implying $2.50-2.80 EPS. STM trades at 35x forward P/E versus pure-play AI infrastructure peers at 50-90x multiples despite multi-domain exposure, with recent 12-month sector comparables showing Vertiv +254%, Tower +560%, MPS +146%, and Infineon +97% versus STM's +208% recovery from November 2025 lows, suggesting a complexity discount that may compress as data center revenue exceeds $1B and simplifies the narrative. Key risks include extended European automotive contraction prolonging P&D underutilization, silicon photonics yield volatility at Crolles facility, SiC commoditization via Onsemi pricing pressure, and single-source dependency on Soitec for proprietary Photonics-SOI substrates that represent a production bottleneck.

Read the full article here. Read time: 15 min

Feintool International Holding (FTON.SW), a Swiss precision parts manufacturer for automotive and industrial applications using fineblanking, forming, and e-lamination stamping technologies, trades at 0.44x price-to-tangible book value, a level reached only 6% of trading days since late 2012, following a major restructuring after weak European EV demand led to a 2024 EBIT loss of -49.3 million CHF. The company has undergone significant transformation, shifting production to low-cost regions in Czech Republic and Hungary, divesting its fineblanking technology segment in 2023, and completing three acquisitions (2017-2021) including Kienle + Spies for 52 million CHF to expand into electric motor components, financed by a 200 million CHF capital raise at 20.50 CHF per share backed by majority shareholder Michael Pieper (50%+ ownership). With 2,850 employees across 18 plants generating 661 million CHF in 2025 sales (58% Europe, 30% USA, 12% Asia, 84% automotive end market), FTON returned to positive 2025 EBIT of 4.7 million CHF despite continued market weakness, supported by restructuring savings scheduled for completion by 2026. Growth catalysts include e-lamination stamping representing 60% of new orders for EV motors, data center cooling applications, positioning in the ZF/BMW 8HP transmission program through the late 2030s, the Volvo EX60 main-motor core supply contract, and a new 15 million CHF India plant opening in Pune, with management maintaining a mid-term EBIT margin target above 6% versus current 0.7%. The company holds a solid balance sheet with 11% net gearing, 180 million CHF in net operating losses (75 million CHF expiring within five years), and potential hidden real estate values with book cost 63% above current book value. Analyst consensus for 2028 projects 691 million CHF sales with 11% EBITDA margins, implying 20.61 CHF per share (+119% upside, 30% CAGR), though risks include persistent weak EU EV demand, industrial market softness, overcapacity, and the unproven ability of the restructured cost base to deliver sustainable returns on lower revenue.

Read the full article here. Read time: 10 min

Bristol-Myers Squibb (BMY) faces a catastrophic revenue decline exceeding 50% from patent cliffs on major products including Eliquis ($14.4 billion in FY2025 sales, generics expected April 2028), Opdivo ($10 billion, US exclusivity lost 2028), Revlimid ($2.9 billion, facing precipitous decline), Pomalyst ($2.7 billion), and a Keytruda royalty ($588 million expiring December 2026), with the company identified as having potentially the largest loss-of-exclusivity exposure relative to revenue among major pharma. The company repurchased $28.3 billion in stock from 2019-2023 at elevated prices but has completely stopped buybacks to fund acquisitions and business development, with net debt rising from $28.9 billion to $35.6 billion despite halted repurchases. BMY spent $3.5 billion in non-contingent payments (plus up to $7.6 billion in milestones) to BioNTech for 50% ownership of pumitamig (BNT327/PM8002), a PD-L1/VEGF bispecific that management believes has 'multi-billion-dollar potential' and will 'transform the standard of care' in over 10 tumor types with plans for 8 registrational studies and launches in seven conditions by 2030. The author argues this investment will be 'torched' because anti-VEGF agents have a history of improving progression-free survival without overall survival benefits in over 50 trials, and the upcoming ASCO presentation of Akeso's ivonescimab (a competing PD-L1/VEGF bispecific) in the Harmoni-6 trial will serve as a critical proof point—if it shows PFS improvement without OS benefit, it validates the thesis that billions were wasted. The author believes BMY's capital allocation has been severely mismanaged and that the company faces potential loss of independence or even bankruptcy, taking a short position in both BMY and Akeso.

Read the full article here. Read time: 10 min